FibroBiologics, Inc. (FBLG) stock
FBLGNasdaqPharmaceutical PreparationsFiscal year ends December 31
$0.90−0.00 (-0.32%)
Close on Nov 17, 2026Market cap $6.00MP/E –Yield –
FibroBiologics operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
FibroBiologics's operating cash flow for the twelve months ending Jun 30, 2026 was -$14.79M. For fiscal 2025 it was -$16.39M.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$16.39M | – |
| FY2024 | Dec 31, 2024 | -$11.90M | – |
| FY2023 | Dec 31, 2023 | -$6.40M | – |
| FY2022 | Dec 31, 2022 | -$4.07M | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$3.29M | – |
| Q1 FY2026 | Mar 31, 2026 | -$4.36M | – |
| Q4 FY2025 | Dec 31, 2025 | -$3.16M | – |
| Q3 FY2025 | Sep 30, 2025 | -$3.97M | – |
| Q2 FY2025 | Jun 30, 2025 | -$3.98M | – |
| Q1 FY2025 | Mar 31, 2025 | -$5.28M | – |
| Q4 FY2024 | Dec 31, 2024 | -$3.07M | – |
| Q3 FY2024 | Sep 30, 2024 | -$2.61M | – |
| Q2 FY2024 | Jun 30, 2024 | -$1.95M | – |
| Q1 FY2024 | Mar 31, 2024 | -$4.28M | – |
| Q4 FY2023 | Dec 31, 2023 | -$1.60M | – |
| Q3 FY2023 | Sep 30, 2023 | -$1.14M | – |
| Q2 FY2023 | Jun 30, 2023 | -$1.63M | – |
| Q1 FY2023 | Mar 31, 2023 | -$2.04M | – |
See a number that looks wrong?